Beam Therapeutics
Develops base-edited medicines for sickle cell disease and inherited metabolic disorders.
Something off on this page? Send us feedback.
Profile
Develops base-edited genetic medicines led by risto-cel for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency, alongside earlier liver-targeted programs. Revenue comes from licenses and collaborations rather than product sales, while development spans ex vivo cell therapy and in vivo lipid-nanoparticle delivery.
Develops investigational genetic medicines using base editing, which makes targeted single-letter DNA changes without double-stranded breaks. The hematology franchise centers on risto-cel, an autologous cell therapy for sickle cell disease. The liver-targeted genetic disease franchise includes BEAM-302 for alpha-1 antitrypsin deficiency, BEAM-301 for glycogen storage disease type Ia, and BEAM-304 for phenylketonuria, using lipid-nanoparticle delivery for in vivo editing.
Combines editing, delivery, clinical development, and internal manufacturing capabilities across U.S. operations in Massachusetts and North Carolina. No medicine has been approved for sale, and revenue to date has come primarily from licensing and collaboration agreements. Progress depends on clinical results, regulatory approval, reliable manufacturing and delivery, collaboration terms, and intellectual-property protection; the business is managed as one operating and reportable segment.
Company facts
Key statistics
Year to date +7.9% · Average volume (30d) 1.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| May 21, 2026 | H.C. Wainwright | Target | $80 | |||
| May 13, 2026 | Tudor Pickering | Target | $41 | $39 | ||
| Feb 25, 2026 | RBC Capital | Reiterate | Sector Perform | $26 | ||
| Feb 20, 2026 | Canaccord Genuity | Target | $74 | |||
| Jan 21, 2026 | Tudor Pickering | Target | $37 | $41 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026Q2 FY26 | −$1.11 | −$1.18 | −6.3% | $16.4M | $490.0K | −97.0% | +9.42% |
| May 7, 2026Q1 FY26 | −$0.87 | −$0.91 | −4.6% | $11.0M | $31.7M | +189.1% | +2.70% |
| Feb 24, 2026Q4 FY25 | −$1.13 | −$0.10 | +91.2% | $11.7M | $114.1M | +877.9% | −8.30% |
| Nov 4, 2025Q3 FY25 | −$0.98 | −$1.10 | −12.2% | $13.2M | $9.7M | −26.6% | +1.45% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.5M | $8.5M | $9.7M | $114.1M | $31.7M | $490.0K | |
| Gross profit | −$91.3M | −$93.3M | −$100.1M | $108.4M | $20.7M | $490.0K | |
| Operating income | −$119.3M | −$120.2M | −$126.8M | −$17.4M | −$107.2M | −$126.6M | |
| Net income | −$109.3M | −$102.3M | −$112.7M | $244.3M | −$94.3M | −$122.7M | |
| Diluted EPS | −$1.24 | −$1.00 | −$1.10 | $2.33 | −$0.91 | −$1.18 | |
| Gross margin | -1,222.8% | -1,102.0% | -1,031.9% | 95.0% | 65.2% | 100.0% | |
| Operating margin | -1,596.9% | -1,419.2% | -1,307.6% | -15.3% | -337.8% | -25,827.1% |
Fiscal years (4-quarter sums)FY21 $51.8M · FY22 $60.9M · FY23 $377.7M · FY24 $63.5M · FY25 $139.7M
Balance sheet, Jun 30, 2026Cash & short-term investments $1.15B · Total debt $247.4M · Total assets $1.39B · Shareholders' equity $1.07B
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 102.88M · Float 88.30M · 85.8% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 12.61M | 12.26% | 13F | Aug 13, 2026 |
| Farallon Capital Management LLC | 10.24M | 9.95% | 13F | Aug 14, 2026 |
| Ark Investment Management LLC | 10.23M | 9.95% | 13F | Aug 14, 2026 |
| BlackRock, Inc. | 9.00M | 8.75% | 13F | Aug 7, 2026 |
| State Street Corp | 5.83M | 5.66% | 13F | Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 27, 2026 | Amy Simon | officer: Chief Medical Officer | −16,667 | $25.74 |
| Jun 30, 2026 | Amy Simon | officer: Chief Medical Officer | −373 | $34.73 |
| Jun 29, 2026 | John M. Evans | director, officer: CEO | −25,000 | $35.49 |
| Jun 30, 2026 | John M. Evans | director, officer: CEO | −25,000 | $34.31 |
| Jun 26, 2026 | FMR LLC | 10 percent owner, other: See Remark 1 | −251,488 | $35.26 |
Peers
- CRISPR Therapeutics
Approved CRISPR SCD therapy and platform benchmark for risto-cel
- Vertex Pharmaceuticals
Commercial CASGEVY owner with SCD access and reimbursement leverage
- Wave Life Sciences
RNA-editing AATD program challenging BEAM-302's root-cause claim
- Arrowhead Pharmaceuticals
Phase 3 RNAi AATD asset competing with BEAM-302 on liver disease
- Intellia Therapeutics
Late-stage in vivo CRISPR benchmark for systemic editing
- Prime Medicine
Prime-editing AATD and liver programs pressure base-editing claims
- Regeneron
Partnered AATD Gene Writing asset backed by large-cap scale
- Editas Medicine
In vivo CRISPR pivot keeps pressure on next-wave SCD editing
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Beam Therapeutics | $29.32 | +0.10% | $3.02B | — | — | 19.3 | −94.2% |
| CRISPR Therapeutics | $57.50 | −0.35% | $5.57B | — | — | 415.7 | +1,041.4% |
| Vertex Pharmaceuticals | $540.78 | −0.17% | $137.48B | 31.5 | 27.8 | 10.9 | +12.5% |
| Wave Life Sciences | $5.09 | +1.07% | $993.1M | — | — | 15.2 | −73.9% |
| Arrowhead Pharmaceuticals | $84.80 | −0.13% | $11.96B | — | — | 17.9 | +171.0% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Prime Medicine | $3.59 | −0.61% | $652.0M | — | — | 160.1 | +3.5% |
| Regeneron | $793.21 | −0.11% | $81.82B | 19.6 | 13.1 | 5.3 | +16.7% |
| Editas Medicine | $3.14 | −0.30% | $484.9M | — | — | 10.3 | +232.3% |
| Median | 25.6 | 20.4 | 16.5 | +14.6% |